XOMA Royalty Corporation (XOMAP) Stock Competitors & Peer Comparison
See (XOMAP) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| XOMAP | $24.98 | +0.00% | 301.3M | 13.72 | $1.82 | +8.63% |
| RPRX | $58.18 | -0.60% | 25B | 11.48 | $5.07 | +1.56% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $90.52 | +0.89% | 9.7B | 258.63 | $0.35 | N/A |
| LQDA | $79.94 | +6.20% | 7.1B | 571.00 | $0.14 | N/A |
| KNSA | $63.95 | +4.65% | 4.8B | 71.06 | $0.90 | N/A |
| VCRE | $11.82 | +1.03% | 3.3B | N/A | N/A | N/A |
| TRLV | $8.79 | +4.52% | 1.5B | -20.88 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
Stock Comparison
XOMAP vs RPRX Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, RPRX has a market cap of 25B. Regarding current trading prices, XOMAP is priced at $24.98, while RPRX trades at $58.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas RPRX's P/E ratio is 11.48. In terms of profitability, XOMAP's ROE is +0.32%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, XOMAP is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RPRX's competition here
XOMAP vs WBA Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, XOMAP is priced at $24.98, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas WBA's P/E ratio is -1.64. In terms of profitability, XOMAP's ROE is +0.32%, compared to WBA's ROE of -0.42%. Regarding short-term risk, XOMAP and WBA have similar daily volatility (0.00).Check WBA's competition here
XOMAP vs CORT Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, CORT has a market cap of 9.7B. Regarding current trading prices, XOMAP is priced at $24.98, while CORT trades at $90.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas CORT's P/E ratio is 258.63. In terms of profitability, XOMAP's ROE is +0.32%, compared to CORT's ROE of +0.08%. Regarding short-term risk, XOMAP is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CORT's competition here
XOMAP vs LQDA Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, LQDA has a market cap of 7.1B. Regarding current trading prices, XOMAP is priced at $24.98, while LQDA trades at $79.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas LQDA's P/E ratio is 571.00. In terms of profitability, XOMAP's ROE is +0.32%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, XOMAP is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check LQDA's competition here
XOMAP vs KNSA Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, KNSA has a market cap of 4.8B. Regarding current trading prices, XOMAP is priced at $24.98, while KNSA trades at $63.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas KNSA's P/E ratio is 71.06. In terms of profitability, XOMAP's ROE is +0.32%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, XOMAP is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check KNSA's competition here
XOMAP vs VCRE Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, VCRE has a market cap of 3.3B. Regarding current trading prices, XOMAP is priced at $24.98, while VCRE trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas VCRE's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to VCRE's ROE of N/A. Regarding short-term risk, XOMAP is less volatile compared to VCRE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check VCRE's competition here
XOMAP vs TRLV Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, XOMAP is priced at $24.98, while TRLV trades at $8.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas TRLV's P/E ratio is -20.88. In terms of profitability, XOMAP's ROE is +0.32%, compared to TRLV's ROE of -0.07%. Regarding short-term risk, XOMAP is less volatile compared to TRLV. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check TRLV's competition here
XOMAP vs HROWL Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, XOMAP is priced at $24.98, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas HROWL's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, XOMAP is less volatile compared to HROWL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HROWL's competition here
XOMAP vs HROWM Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, XOMAP is priced at $24.98, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas HROWM's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, XOMAP is less volatile compared to HROWM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HROWM's competition here
XOMAP vs AVLN Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, AVLN has a market cap of 1.3B. Regarding current trading prices, XOMAP is priced at $24.98, while AVLN trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas AVLN's P/E ratio is -1.30. In terms of profitability, XOMAP's ROE is +0.32%, compared to AVLN's ROE of +0.36%. Regarding short-term risk, XOMAP is less volatile compared to AVLN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check AVLN's competition here
XOMAP vs CGEM Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, CGEM has a market cap of 1.1B. Regarding current trading prices, XOMAP is priced at $24.98, while CGEM trades at $17.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas CGEM's P/E ratio is -5.26. In terms of profitability, XOMAP's ROE is +0.32%, compared to CGEM's ROE of -0.51%. Regarding short-term risk, XOMAP is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CGEM's competition here
XOMAP vs TBPH Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, TBPH has a market cap of 877.5M. Regarding current trading prices, XOMAP is priced at $24.98, while TBPH trades at $16.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas TBPH's P/E ratio is -222.18. In terms of profitability, XOMAP's ROE is +0.32%, compared to TBPH's ROE of +0.44%. Regarding short-term risk, XOMAP is less volatile compared to TBPH. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check TBPH's competition here
XOMAP vs IKT Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, IKT has a market cap of 265.4M. Regarding current trading prices, XOMAP is priced at $24.98, while IKT trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas IKT's P/E ratio is -4.67. In terms of profitability, XOMAP's ROE is +0.32%, compared to IKT's ROE of -0.41%. Regarding short-term risk, XOMAP is less volatile compared to IKT. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check IKT's competition here
XOMAP vs LFMD Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, LFMD has a market cap of 200.7M. Regarding current trading prices, XOMAP is priced at $24.98, while LFMD trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas LFMD's P/E ratio is -10.73. In terms of profitability, XOMAP's ROE is +0.32%, compared to LFMD's ROE of -1.72%. Regarding short-term risk, XOMAP is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check LFMD's competition here
XOMAP vs HITI Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, HITI has a market cap of 196.8M. Regarding current trading prices, XOMAP is priced at $24.98, while HITI trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas HITI's P/E ratio is 56.00. In terms of profitability, XOMAP's ROE is +0.32%, compared to HITI's ROE of -0.43%. Regarding short-term risk, XOMAP is less volatile compared to HITI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HITI's competition here
XOMAP vs LFMDP Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, LFMDP has a market cap of 159M. Regarding current trading prices, XOMAP is priced at $24.98, while LFMDP trades at $23.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas LFMDP's P/E ratio is 288.60. In terms of profitability, XOMAP's ROE is +0.32%, compared to LFMDP's ROE of -1.72%. Regarding short-term risk, XOMAP is less volatile compared to LFMDP. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check LFMDP's competition here
XOMAP vs CIRC Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, CIRC has a market cap of 69.5M. Regarding current trading prices, XOMAP is priced at $24.98, while CIRC trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas CIRC's P/E ratio is -1.76. In terms of profitability, XOMAP's ROE is +0.32%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, XOMAP is less volatile compared to CIRC. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CIRC's competition here
XOMAP vs PETS Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, PETS has a market cap of 42.1M. Regarding current trading prices, XOMAP is priced at $24.98, while PETS trades at $1.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas PETS's P/E ratio is -1.86. In terms of profitability, XOMAP's ROE is +0.32%, compared to PETS's ROE of -1.47%. Regarding short-term risk, XOMAP is less volatile compared to PETS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check PETS's competition here
XOMAP vs RAD Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, XOMAP is priced at $24.98, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas RAD's P/E ratio is -0.05. In terms of profitability, XOMAP's ROE is +0.32%, compared to RAD's ROE of +2.76%. Regarding short-term risk, XOMAP is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RAD's competition here
XOMAP vs SDEV Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, SDEV has a market cap of 35M. Regarding current trading prices, XOMAP is priced at $24.98, while SDEV trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas SDEV's P/E ratio is -0.23. In terms of profitability, XOMAP's ROE is +0.32%, compared to SDEV's ROE of +17.15%. Regarding short-term risk, XOMAP is less volatile compared to SDEV. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SDEV's competition here
XOMAP vs GLTO Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, XOMAP is priced at $24.98, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas GLTO's P/E ratio is -1.78. In terms of profitability, XOMAP's ROE is +0.32%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, XOMAP is less volatile compared to GLTO. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check GLTO's competition here
XOMAP vs KYNB Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, KYNB has a market cap of 29.3M. Regarding current trading prices, XOMAP is priced at $24.98, while KYNB trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas KYNB's P/E ratio is -0.59. In terms of profitability, XOMAP's ROE is +0.32%, compared to KYNB's ROE of -2.34%. Regarding short-term risk, XOMAP is less volatile compared to KYNB. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check KYNB's competition here
XOMAP vs SCYX Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, SCYX has a market cap of 26.9M. Regarding current trading prices, XOMAP is priced at $24.98, while SCYX trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas SCYX's P/E ratio is -1.25. In terms of profitability, XOMAP's ROE is +0.32%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, XOMAP is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SCYX's competition here
XOMAP vs NSRX Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, NSRX has a market cap of 25.9M. Regarding current trading prices, XOMAP is priced at $24.98, while NSRX trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas NSRX's P/E ratio is -4.18. In terms of profitability, XOMAP's ROE is +0.32%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, XOMAP is less volatile compared to NSRX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check NSRX's competition here
XOMAP vs RNTX Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, RNTX has a market cap of 24.1M. Regarding current trading prices, XOMAP is priced at $24.98, while RNTX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas RNTX's P/E ratio is -0.49. In terms of profitability, XOMAP's ROE is +0.32%, compared to RNTX's ROE of -2.58%. Regarding short-term risk, XOMAP is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check RNTX's competition here
XOMAP vs BFRI Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, BFRI has a market cap of 14M. Regarding current trading prices, XOMAP is priced at $24.98, while BFRI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas BFRI's P/E ratio is -1.02. In terms of profitability, XOMAP's ROE is +0.32%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, XOMAP is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check BFRI's competition here
XOMAP vs MEDS Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, XOMAP is priced at $24.98, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas MEDS's P/E ratio is -0.31. In terms of profitability, XOMAP's ROE is +0.32%, compared to MEDS's ROE of -1.21%. Regarding short-term risk, XOMAP is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check MEDS's competition here
XOMAP vs MSLE Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, MSLE has a market cap of 11.5M. Regarding current trading prices, XOMAP is priced at $24.98, while MSLE trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas MSLE's P/E ratio is -6.57. In terms of profitability, XOMAP's ROE is +0.32%, compared to MSLE's ROE of -0.67%. Regarding short-term risk, XOMAP is less volatile compared to MSLE. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check MSLE's competition here
XOMAP vs CJJD Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, XOMAP is priced at $24.98, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas CJJD's P/E ratio is -0.46. In terms of profitability, XOMAP's ROE is +0.32%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, XOMAP is less volatile compared to CJJD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CJJD's competition here
XOMAP vs SSY Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, XOMAP is priced at $24.98, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas SSY's P/E ratio is -2.86. In terms of profitability, XOMAP's ROE is +0.32%, compared to SSY's ROE of -0.09%. Regarding short-term risk, XOMAP is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SSY's competition here
XOMAP vs POM Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, POM has a market cap of 7.2M. Regarding current trading prices, XOMAP is priced at $24.98, while POM trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas POM's P/E ratio is -0.21. In terms of profitability, XOMAP's ROE is +0.32%, compared to POM's ROE of +0.16%. Regarding short-term risk, XOMAP is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check POM's competition here
XOMAP vs HKPD Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, HKPD has a market cap of 4.2M. Regarding current trading prices, XOMAP is priced at $24.98, while HKPD trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas HKPD's P/E ratio is -6.33. In terms of profitability, XOMAP's ROE is +0.32%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, XOMAP is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check HKPD's competition here
XOMAP vs PAVS Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, PAVS has a market cap of 3.6M. Regarding current trading prices, XOMAP is priced at $24.98, while PAVS trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas PAVS's P/E ratio is -0.05. In terms of profitability, XOMAP's ROE is +0.32%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, XOMAP is less volatile compared to PAVS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check PAVS's competition here
XOMAP vs MDVL Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, XOMAP is priced at $24.98, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas MDVL's P/E ratio is -0.05. In terms of profitability, XOMAP's ROE is +0.32%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, XOMAP is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check MDVL's competition here
XOMAP vs ATNFW Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, XOMAP is priced at $24.98, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas ATNFW's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, XOMAP is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check ATNFW's competition here
XOMAP vs BGMSP Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, XOMAP is priced at $24.98, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, XOMAP's ROE is +0.32%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, XOMAP is less volatile compared to BGMSP. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check BGMSP's competition here
XOMAP vs BGMS Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, BGMS has a market cap of 2.1M. Regarding current trading prices, XOMAP is priced at $24.98, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas BGMS's P/E ratio is -0.27. In terms of profitability, XOMAP's ROE is +0.32%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, XOMAP is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check BGMS's competition here
XOMAP vs AZNH Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, XOMAP is priced at $24.98, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas AZNH's P/E ratio is 38.35. In terms of profitability, XOMAP's ROE is +0.32%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, XOMAP is less volatile compared to AZNH. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check AZNH's competition here
XOMAP vs LFLYW Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, XOMAP is priced at $24.98, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, XOMAP's ROE is +0.32%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, XOMAP and LFLYW have similar daily volatility (0.00).Check LFLYW's competition here
XOMAP vs SBFMW Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, SBFMW has a market cap of 174.7K. Regarding current trading prices, XOMAP is priced at $24.98, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas SBFMW's P/E ratio is -0.01. In terms of profitability, XOMAP's ROE is +0.32%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, XOMAP is less volatile compared to SBFMW. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check SBFMW's competition here
XOMAP vs POZN Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, POZN has a market cap of 0. Regarding current trading prices, XOMAP is priced at $24.98, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas POZN's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to POZN's ROE of +0.61%. Regarding short-term risk, XOMAP is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check POZN's competition here
XOMAP vs OREX Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, OREX has a market cap of 0. Regarding current trading prices, XOMAP is priced at $24.98, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas OREX's P/E ratio is -0.14. In terms of profitability, XOMAP's ROE is +0.32%, compared to OREX's ROE of -0.54%. Regarding short-term risk, XOMAP is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check OREX's competition here
XOMAP vs CPD Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, CPD has a market cap of 0. Regarding current trading prices, XOMAP is priced at $24.98, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas CPD's P/E ratio is N/A. In terms of profitability, XOMAP's ROE is +0.32%, compared to CPD's ROE of N/A. Regarding short-term risk, XOMAP is less volatile compared to CPD. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check CPD's competition here
XOMAP vs SHPG Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, XOMAP is priced at $24.98, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas SHPG's P/E ratio is 11.35. In terms of profitability, XOMAP's ROE is +0.32%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, XOMAP and SHPG have similar daily volatility (0.00).Check SHPG's competition here
XOMAP vs ESRX Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, XOMAP is priced at $24.98, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas ESRX's P/E ratio is 10.69. In terms of profitability, XOMAP's ROE is +0.32%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, XOMAP and ESRX have similar daily volatility (0.00).Check ESRX's competition here
XOMAP vs IPXL Comparison July 2026
XOMAP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XOMAP stands at 301.3M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, XOMAP is priced at $24.98, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XOMAP currently has a P/E ratio of 13.72, whereas IPXL's P/E ratio is -2.63. In terms of profitability, XOMAP's ROE is +0.32%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, XOMAP is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for XOMAP.Check IPXL's competition here